-
Depo-Provera Meningioma Cases: Women With At Least 4 Years Use or Starting Injections After Age 31
Higher Risk Of Meningioma Side Effects Associated With Depo-Provera for These Women, According to a 2025 Medical Study Report (Posted by Tom Lamb at Drug Injury Watch) A recent medical study looking at Depo-Provera meningioma cases in…
-
Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness
Semaglutide is the Active Ingredient in These GLP-1 Drugs Used for Diabetes or Weight Loss (Posted by Tom Lamb at Drug Injury Watch) Over the past year, we have written several articles that reference medical reports concerning…
-
Dupixent Lawsuits Being Filed for Patients: Medical Information and Legal Allegations
These Dupixent Cases Involving T-cell Lymphoma Cancer Are Against Regeneron Pharmaceuticals and Sanofi-Aventis (Posted by Tom Lamb at Drug Injury Watch) We are currently investigating possible Dupixent lawsuits for patients who were diagnosed with a relatively rare…
-
Dupixent Drug Injury Lawsuits For Patients Diagnosed With CTCL Cancer
Cutaneous T-cell Lymphoma (CTCL) Cancer Includes Mycosis Fungoides And Sézary Syndrome (Posted by Tom Lamb at Drug Injury Watch) A growing body of medical evidence showing an association between Dupixent and cutaneous T-cell lymphoma (CTCL) has given…
-
More Evidence For Increased Risk of NAION With Ozempic or Mounjaro in Diabetes Patients
NAION is Likely Associated With Other Semaglutide or Tirzepatide GLP-1RA Drugs Used for Weight Loss (Posted by Tom Lamb at Drug Injury Watch) A new medical article published August 11, 2025, online by JAMA Network…
-
Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs
Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION)…
